Tirzepatide in PCOS: real-world weight loss matches women without PCOS

Summary

A retrospective open-cohort study published in the Journal of the Endocrine Society (19 August 2026) looked at 4,241 women with self-reported PCOS using tirzepatide through a UK digital weight-management service. At 10 months, mean weight loss was −19.40% (95% CI −22.38 to −16.42) in women with PCOS versus −18.74% (95% CI −19.67 to −17.81) in women without PCOS — a difference that was not statistically significant (p = 0.68). In the PCOS group, 96.6% had lost at least 5% of their body weight, 90.8% at least 10% and 57.7% at least 20%. Higher engagement with the service's digital coaching was associated with an extra 3.42% weight loss in absolute terms (p < 0.001). Two limitations matter when reading those numbers: PCOS was self-reported, not confirmed against Rotterdam criteria, and only 40 women with PCOS were still in follow-up at the 10-month mark, so the long-horizon estimate rests on a small, probably self-selected group. This is observational real-world data, not a randomised trial, and it reports weight only — no cycle, ovulation or androgen outcomes.